Lundbeck bets on four core products during hard year

While Northera sales plummeted more rapidly than expected, Lundbeck plans for its other products to make up for this loss, especially now that the migraine drug Vyepti is gaining momentum.

Lundbeck CFO Anders Götzsche. | Photo: BUNDGAARD CARSTEN/ERH

On Tuesday, Lundbeck brought a pleasant surprise to the market by presenting its report for Q1 which was better than anticipated, both in terms of the bottom line and the top line.

The company advanced in spite of the fact that the expiration of the patent for the drug Northera hit the company harder than expected, and it seems this development will carry on.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs